Beyond inhibition: harnessing the DRD2–VEGF-A feedback loop for precision anti-angiogenesis therapy in cancer
-
By
-
Manas Ranjan Sahu
-
Venu Akkanapally
-
Partha Sarathi Dasgupta
-
Sujit Basu
-
May 28, 2026
-
Clinical Scorecard: Exploiting the DRD2–VEGF-A Feedback Mechanism for Targeted Anti-Angiogenesis Treatment in Oncology
At a Glance
| Category | Detail |
|---|
| Condition | Tumor angiogenesis |
| Key Mechanisms | DRD2/VEGF-A paracrine feedback loop |
| Target Population | Patients with tumors exhibiting VEGF-A dependency |
| Care Setting | Oncology |
Key Highlights
- DRD2 activation selectively inhibits VEGFR2 phosphorylation in tumor endothelial cells.
- Cabergoline and other DRD2 agonists can suppress tumor growth by targeting aberrant angiogenesis.
- Dynamic imaging can assess tumor VEGF-dependency for precision treatment selection.
Guideline-Based Recommendations
Diagnosis
- Utilize dynamic contrast-enhanced MRI to assess vascular permeability.
Management
- Implement a Dopaminergic Challenge using DRD2 agonists to identify VEGF-dependency.
Monitoring & Follow-up
- Monitor changes in vascular permeability post-DRD2 agonist administration.
Risks
- Potential systemic toxicities from prolonged nonselective anti-VEGF therapies.
Patient & Prescribing Data
Patients with tumors showing fluctuating VEGF-A dependency.
DRD2 agonists like cabergoline have a well-characterized safety profile.
Clinical Best Practices
- Use high-resolution spatial transcriptomic mapping for precision stratification.
- Assess endothelial DRD2 expression as a biomarker for treatment responsiveness.
Related Resources & Content
